20th Annual Fall Midwest Thoracic and GI Oncology Conference

We look forward to welcoming you to our two-day conference focused on the latest advancements in the management of thoracic and gastrointestinal (GI) malignancies.

Whether you’re attending one day or both, you’ll benefit from a comprehensive learning experience designed for multidisciplinary care teams.

Day 1: Thoracic
Gain insights into current and emerging strategies for the management of sarcomas, thymic tumors, and small-cell lung cancer. Sessions will also address best practices in post-thoracic surgical pain management and highlight considerations for complex case management across disease stages.

Day 2: GI
Explore two decades of progress in GI cancer care, including advances in systemic therapies, considerations for treating older adults, and the integration of patient perspectives into clinical decision-making. Presentations will emphasize real-world approaches and interprofessional collaboration.

This conference is designed to provide oncology professionals with clinically relevant, evidence-based updates across a spectrum of disease states, with practical applications for multidisciplinary care teams.

At the conclusion of this activity, the participants should be better able to:

Thoracic:

1. Discuss current management options for patients diagnosed with sarcoma.
2. Implement evidence-based treatment plans for patients with thymomas and thymic carcinomas.
3. Develop comprehensive strategies for managing all stages of small-cell lung cancer.
4. Institute effective pain management protocols following thoracic surgery.

GI:

1. Review advancements in gastrointestinal (GI) cancer management over the past two decades.
2. Integrate patient perspectives into cancer diagnosis and treatment planning.
3. Identify key considerations and adapt oncologic care for patients aged 80 and older.

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Nebraska Medicine. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

FULL CONFERENCE

The University of Nebraska Medical Center designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

THORACIC

The University of Nebraska Medical Center designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GI

The University of Nebraska Medical Center designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

FULL CONFERENCE

14.5 Contact Hours Awarded
Nebraska Medicine is approved as a provider of nursing continuing professional development by VTL Center for Professional Development, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

THORACIC

7.25 Contact Hours Awarded 
Nebraska Medicine is approved as a provider of nursing continuing professional development by VTL Center for Professional Development, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

GI

7.25 Contact Hours Awarded
Nebraska Medicine is approved as a provider of nursing continuing professional development by VTL Center for Professional Development, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Read the UNMC CCE Disclosure Declaration Policy 

Disclosures

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles.

FACULTY

The following have disclosed relevant financial relationships:

• Apar Kishor Ganti, MD
  Consultant: AstraZeneca; Cardinal Health; Jazz Pharmaceuticals, Inc.
  Research Support: Chimerix (A Jazz Pharmaceuticals Company)
  UNMC Institutional Principal Investigator: Imugene Limited; IOVANCE Biotherapeutics, Inc.; Merck & Co, Inc.; Mirati Therapeutics; Poseida Therapeutics, Inc.
  INVESTIGATIONAL/OFF-LABEL USE OF DRUGS DISCLOSURE: The majority of the drugs used for thymoma are not approved for that specific indication
• Kelsey Klute, MD
  Consultant: Bristol-Myers Squibb; Ipsen Pharma; Partner Therapeutics, Inc.
• Sean V. McGarry, MD
  Medical Board of Trustees: MTF Biologics (a registered trademark of the Musculoskeletal Transplant Foundation)
• Kate-Lynn E. Muir, DO
  Advisory Board: Bristol-Myers Squibb
• Aaron R. Sasson, MD
  Owner: Sanguine Diagnostics and Therapeutics

The following have nothing to disclose:

• Omar Abughanimeh, MBBS
• Stacie Adcock
• David B. Berkheim, MD
• Lisa M. Brown, MD, MAS
• Matt DeVries, MD
• Jason M. Foster, MD, FACS
• Jean Grem, MD
• Ashley L. Hein, MD
• Jessica L. Kalender-Rich, MD, MHA
• Qateeb Khan, MD
• Mridula Krishnan, MBBS
• Rudy P. Lackner, MD, FACS, FCCP*
• Erik E. Lewis, MD
• Chi Lin, MD, PhD, MS
• Quan P. Ly, MD, FACS*
• Meghan Oakes, MD, FACOG
• Terri Osborn
• Leiauna Pelster, MMN, RD, LMNT
• Andrew Wahl, MD
• Cheyenne Watkins, MS, RDN, LMNT

PLANNING COMMITTEE

The following has disclosed relevant financial relationships:

• Quan P. Ly, MD, FACS
  Stockholder: Amgen Inc.; Bayer AG: Biogen; Bristol-Myers Squibb; Intuitive Surgical Operations, Inc.; Merck & Co., Inc; Moderna, Inc.; Novartis AG; Organon; Perrigo Company plc; Pfizer Inc.; Sanofi; ThermoGenesis; Vaso Corporation; Viatris Inc.

The following have nothing to disclose:

• Missy Edwards
• Julie Huglin
• Jackie Siebels, BSN, RN, NPD-BC

*Faculty and Planning Committee member